Commercial adoption of the LIBERTY System by sites that participated in the clinical trial serves as a strong validation of the value it brings to everyday practice

The Company will attend the Annual Global Embolization Symposium & Technologies (GEST), a Premier Medical Conference in New York City that attracts over 1,000 global experts across key target call points

 

HINGHAM, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, which is experiencing strong interest from physicians and hospital executives following the commencement of the Full Market Release of LIBERTY at the recent Society of Interventional Radiology (SIR) annual meeting, has since won accounts in key sales territories, including two accounts that participated in the ACCESS-PVI pivotal clinical trial.

The Company continues to benefit from growing commercial interest, supported by recently updated medical guidelines aimed at reducing radiation exposure and improving ergonomic challenges that have contributed to staffing challenges in interventional care. The Company expects to further raise its profile at the Annual Global Embolization Symposium & Technologies (GEST) Conference, being held in New York City from May 14-17, 2026. GEST attracts a global network of over 1,000 Interventional Radiologists (IR) and Interventional Oncologists (IO), where they meet to advance embolotherapy, learn about the latest innovative techniques, and launch the newest products.

With physicians attending from around the world, participation in the upcoming GEST conference represents a further step in expanding the Company's footprint to ultimately establish a global commercial infrastructure. This effort is supported by the recent appointment of Alon Tamir as Vice President of Sales, EMEA, to lead commercialization across key international markets.